The Quantellect read.As of Nov 19, 2026, 11 active firms cover Zymeworks Inc. Common Stock: 11 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $32.00 to $58.00, a moderate spread. The average target of $43.00 sits 65% above the current $26.06. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 10 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.40 next quarter toward $0.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy11100%
Neutral00%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$43.00
+65.0% upside
Average target across 10 active firms as of Nov 19, 2026 vs $26.06 current
Highest Target$58.00
Average Target$43.00
Lowest Target$32.00
Detailed analyst forecasts for ZYME
Showing 1–12 of 12 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 11 of 11 active firms rate ZYME a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ZYME EPS & revenue forecast
EPS · NEXT QUARTER
$-0.40
Range $-0.47 – $-0.32 · 2 analysts · -33% YoY
Next period, 2 analysts expect Zymeworks Inc. Common Stock to earn $-0.40 a share (range $-0.47 – $-0.32), versus $-0.59 a year earlier. Full-year consensus is $1.51, growing to $0.30 the year after.
REVENUE · NEXT QUARTER
$36.0M
Range $36.0M – $36.0M · 2 analysts · +1395% YoY
Revenue is expected to reach $36.0M (range $36.0M – $36.0M), +1395.0% year-over-year. Full-year consensus is $339.3M, rising to $348.2M next year.
Top analysts covering Zymeworks Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZYME.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$44.00+68.8% to target
Overall win rate
49%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Buy
$33.00+26.6% to target
Overall win rate
51%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #162
Buy
$58.00+122.6% to target
Overall win rate
53%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$56.00+114.9% to target
Overall win rate
42%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$39.00+49.7% to target
Overall win rate
38%
+ Follow
ZYME stock forecast FAQ
What is ZYME's average 12-month price target?+
The 10 active firms with a live target average $43.00 for Zymeworks Inc. Common Stock over the next 12 months, ranging from a $58.00 high to a $32.00 low, as of Nov 19, 2026.
Is ZYME stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ZYME?+
The Street-high target is $58.00 (Leerink Partners), and the Street-low is $32.00 (Citizens). The average of all 10 active-firm targets is $43.00.
How many active Wall Street firms cover ZYME?+
11 active firms have a recognized rating on Zymeworks Inc. Common Stock as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ZYME?+
Among analysts who currently cover ZYME, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $44.00 target.
What is Zymeworks Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.40 per share (range $-0.47 – $-0.32) across 2 analysts. Full-year EPS is projected at $1.51, rising to $0.30 the following year.
How much revenue is Zymeworks Inc. Common Stock expected to report next quarter?+
Consensus revenue is $36.0M (range $36.0M – $36.0M). Full-year revenue is projected at $339.3M, growing to $348.2M next year.
Have analysts been upgrading or downgrading ZYME lately?+
As of Nov 19, 2026, 11 of 11 active firms rate ZYME a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZYME calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.